Newsletter Volume 40, Number 1, 2025
Introduction
As the year 2025 begins, we welcome you to the first issue of this newsletter. Many events have been taking place in the world this year. The ceasefire in Gaza and the reappointment of former President Trump are hot topics, while the war that began with Russia’s invasion of Ukraine has yet to come to an end. As I feel the instability of the international situation on a daily basis, I am reminded of how the development of science and technology can contribute to peace and a sustainable society.
I myself am preparing to move to the United Kingdom in April for joint research, and I have heard that it will take four to five months to transport goods by ship due to the Suez Canal traffic restrictions, and that air transportation costs have risen significantly from a few years ago due to the inability to fly over Russia. I realized that the world is moving in ways that affect our immediate surroundings.
The other day, I had an opportunity to talk with one of my former professors, who told me that it is important not only to know the world, but also to join the circle of researchers around the world and discuss things on an equal footing. I feel again the importance of building an international network and developing research in the field of pharmacokinetic research, and I think it is important for JSSX to build an environment where individual researchers can actively engage in activities, while further deepening cooperation with ISSX. This year’s JSSX Annual Meeting will be held in Kyoto, and we hope that new discoveries and connections will be made through active face-to-face discussions.
In this newsletter, we will provide you with up-to-date research results, reports on conference activities, and other useful information. We look forward to your continued support and cooperation. (T.Y.)
NEW POWER for pharmacokinetic research
The Frontier of Democratization of Drug Discovery: The Pursuit of the World’s Best Pharmacokinetic Researchers
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Keio University
Satoyo Tsuchiya
My name is Satoyoh Tsuchiya, and I am a member of the Faculty of Pharmaceutical Sciences at Keio University. I would like to express my sincere gratitude to the editorial board members for the opportunity to contribute to the newsletter of the Japanese Pharmacokinetics Society. I entered the Department of Pharmacy, Faculty of Pharmaceutical Sciences, Keio University in 2012, and upon obtaining my national pharmacist license in 2018, I entered the doctoral program and received my degree in March 2022. After that, I did research activities as a post-doctoral fellow at the iHuman Research Institute, Shanghai University of Science and Technology in Shanghai, China, and then I joined the Department of Pharmaceutics, Faculty of Pharmacy, Keio University in August 2024, where I am currently working. Including my undergraduate days, this is the third laboratory I have belonged to. … ( To be continued at NL website / Members Only )
Research on the Pharmacokinetics of Targeted Protein Degradation D rugs ( TPDs ) in the Body
Part 1: Introduction: Concept of targeted protein degrader
Astellas Pharma Inc. Non-clinical Biomedical Science
Fumio Osaki
Welcome to the third installment of the introduction to pharmacokinetic research in R&D of New modality, “Targeted protein degrader (TPD)”. Targeted protein degraders are a new “small molecule” modality that has been attracting much attention and expectation. In this three-part series, we will discuss how to evaluate its unique properties from the viewpoint of pharmacokinetics and translational research, and how to predict its efficacy in clinical practice. In the first article, I will explain the modality of the targeted protein degrader as an introduction to this series. … ( To be continued at NL website / members only )